Roivant Announces Completion of Redemption of its Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) — Roivant (Nasdaq:…
Month: September 2023
Roivant Announces Completion of Redemption of its Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) — Roivant (Nasdaq:…
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Longeveron Issues Letter to Stockholders
MIAMI, Sept. 11, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
Longeveron Issues Letter to Stockholders
MIAMI, Sept. 11, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical…
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical…
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease
Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological…
BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease
Data from Phase 3 Trial of NE3107 Presented as Poster at the 148th American Neurological…
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients…
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients…
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI),…
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI),…
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 WALTHAM, Mass., Sept….